Skip to main content
Gilead10-Q: Acquisition completed

Completed acquisitions of Arcellx, Tubulis, and Ouro Medicines incurring $11.2 billion IPR&D

Source: Autobound Signal API · 74 signals tracked for Gilead · updated

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.

What happened

Gilead completed acquisitions of Arcellx ($7.0 billion), Tubulis ($3.1 billion), and Ouro Medicines ($1.0 billion net) in the second quarter of 2026.

Source

SEC EDGARAug 6, 2026

Quarterly report (Form 10-Q)

Gilead 10-Q for Quarter ended Jun 30, 2026

Filing excerpt

Acquired in-process research and development expenses were $11.2 billion for the three months ended June 30, 2026, primarily related to the following transactions: $7.0 billion Arcellx acquisition; $3.1 billion Tubulis acquisition; and $1.0 billion Ouro Medicines acquisition

sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htmRead the full source

Other signals in this filing (5)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Acquisition completed

What this signalsIntegration work after a deal often opens needs for new systems and services.

Period
Quarter ended Jun 30, 2026
Fiscal year end
06/30
Filed
Aug 6, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$11.2B (acquired IPR&D expenses for Arcellx, Tubulis, and Ouro Medicines acquisitions)

Details

CIK
882095
Accession number
0000882095-26-000031
Timeframe
Current quarter
Quarter
Q2
Filing year
2026
Period end date
Jun 30, 2026
Why it matters
Active integration needs
Signal category
Strategic

Topics and mentions

Technologies

  • antibody-drug conjugate
  • ADC
  • CAR T-cell

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
acquisitionCompleted

Use this data

Get every 10-Q signal for Gilead and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/1e8ffd99-0052-4a06-8b31-9e98a89b7c31 returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.

{
  "signal_id": "1e8ffd99-0052-4a06-8b31-9e98a89b7c31",
  "signal_type": "sec-10q",
  "signal_subtype": "acquisitionCompleted",
  "detected_at": "2026-11-09T06:32:59.422+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "detail": "Gilead completed acquisitions of Arcellx ($7.0 billion), Tubulis ($3.1 billion), and Ouro Medicines ($1.0 billion net) in the second quarter of 2026. This massive pipeline expansion and ongoing integration could create vendor evaluation opportunities for integration consulting, specialized lab software, and clinical IT systems.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "acquired IPR&D expenses for Arcellx, Tubulis, and Ouro Medicines acquisitions",
      "dollar_millions": 11183
    },
    "quarter": "Q2",
    "summary": "Completed acquisitions of Arcellx, Tubulis, and Ouro Medicines incurring $11.2 billion IPR&D",
    "excerpts": "Acquired in-process research and development expenses were $11.2 billion for the three months ended June 30, 2026, primarily related to the following transactions: $7.0 billion Arcellx acquisition; $3.1 billion Tubulis acquisition; and $1.0 billion Ouro Medicines acquisition",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm",
    "filing_date": "2026-08-06",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "06/30",
    "period_end_date": "2026-06-30",
    "sales_relevance": "Active integration needs",
    "signal_category": "strategic",
    "technologies_mentioned": [
      "antibody-drug conjugate",
      "ADC",
      "CAR T-cell"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.